Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System

News   Mar 09, 2017

 
Agilent Technologies Extends Biopharma Portfolio with Advanced Mass Spec System
 
 
 

RELATED ARTICLES

Novel Therapeutic Target for Breast Cancer

News

Research has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an emerging hallmark of cancer. The finding identifies a new target for therapeutic intervention in breast cancer.

READ MORE

DNA ‘Shield’ Discovered with Crucial Roles in Normal Cell Division, the Immune System & Cancer

News

Scientists have made a major discovery about how cells repair broken strands of DNA that could have huge implications for the treatment of cancer.

READ MORE

Genetic Factors Leading to Rare Bone Fusion Disorder Identified

News

Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusion

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy